Method validation for quantification of carbamazepine in fingerprints deposited on glass cover slips

INTRODUCTION: About 38 million people are exposed to carbamazepine per year for the treatment of epilepsy. The drug is on the WHO essential list. The treatment for epilepsy happens in a prophylactic way, to provide the patient with a better life condition. Therefore, in addition to the choice of medication and the dose required for everyone, adherence to therapy is also of great importance in the functioning of the treatment. Fingerprint is widely used in the forensic area, this matrix is ​​also appearing in the toxicological and clinical area, to find out if the individual has ingested a substance. MATERIAL AND METHOD: A method was validated in High Performance Liquid Chromatography coupled to Mass Spectrometry, following the validation parameters of the Food and Drug Administration for the quantification of carbamazepine (CBZ) in fingerprints. RESULTS: The method demonstrated high sensitivity for detecting CBZ in fingerprint samples. The detection limit of the method was 0.05 ng digital-1 for CBZ. The intra-assay precision ranged from 3.58 to 7.90%. The inter-assay precision was 2.16 to 5.79% for CBZ. The accuracy presented by the method ranged from 95.02 to 102.76%. DISCUSSION: Liquid chromatography conditions play a key role in achieving fast and effective component separation and ionization. CONCLUSION: Thus, a simple and sensitive method is being validated for CBZ quantification in fingerprint samples deposited on glass slides.